Effect of Celecoxib on Markers of Vascular Inflammation
Completed · Phase 4 · Has a placebo group
Conditions studied: Hypertension and Coronary Artery Disease
In brief
This study involves a drug called celecoxib, which is commonly prescribed for people with arthritis. Arthritis is caused by inflammation of the joints or tissues. Inflammation also occurs in the blood vessels that lead to your heart, and the purpose of this study is to see if celecoxib can reduce the blood vessel inflammation associated with high cholesterol and heart disease.
Key facts
- Study ID
- NCT00471341
- Run by
- University of Florida
- People needed
- 75
- Starts
- 2002-07-01
- Expected to finish
- 2004-12-01
- Last updated by the study team
- 2011-09-19
Who can join
Age: 50 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Age greater than or equal to 50 years old
- Hypertension documented and treated according to the 6th report of the Joint National Committee on Detection and Evaluation of the treatment of high blood pressure (JNC VI)
- Documented coronary artery disease, defined as classic stable angina pectoris, previous myocardial infarction (more than 1 month ago) or unstable angina (more than 1 month ago), abnormal coronary angiogram, or concordant abnormalities on two different types of stress tests
- Dyslipidemia requiring medical therapy with HMG CoA Reductase inhibitors, and treated according to NCEP II guidelines for cholesterol lowering
- Diabetes, if treated according to ADA guidelines for diabetes
- Classic angina, if treated according to ACC/AHA guidelines for angina control
- Therapy with an HMG CoA Reductase inhibitor for at least 3 months
- Willingness to provide informed consent
You may not qualify if…
- PUD
- Coronary Artery Bypass Surgery or PTCA in the past 6 months
- Active infection
- Weight < 50Kg
- History of a hematologic bleeding disorder
- History of gastrointestinal bleeding
- Allergy to aspirin or celecoxib or other NSAIDs or sulfonamides
- Allergy or intolerance to HMG CoA Reductase inhibitor therapy
- Stroke within 1 month of enrollment
- History of a chronic inflammatory disease
- History of asthma
- History of hepatic disorder
- Advanced renal disease (Serum Creatinine > 3mg/dl)
- Anticipated need for therapy with NSAIDs within the 3 month period of the study
- Chronic therapy (14 consecutive days) with any NSAID in the last 30 days
Where it is running
- University of Florida — Gainesville, Florida, United States
- University of Texas Health Science Center — Houston, Texas, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.